Zeger G, Williams C T, Shulman I A
Transfusion Service, University of Southern California (USC) University Hospital, USA.
Transfus Sci. 1997 Dec;18(4):585-8. doi: 10.1016/s0955-3886(97)00057-x.
One of the strategies to reduce the risk of harming a patient by transfusion therapy is to limit the overall risk of transfusion-transmitted disease. Central to this approach is minimizing the number of allogeneic blood products with which a patient is transfused. The usual dose of platelets for an adult patient is either six to 10 random donor platelets vs. one unit of platelets, pheresis (so-called single donor apheresis platelets). Consequently, the transfusion services at the University of Southern California Health Sciences Campus (USC University Hospital, the Norris Cancer Hospital, and Los Angeles County + USC Medical Center) routinely use single donor apheresis platelets (SDPs) rather than random donor platelets (RDPs) in an effort to minimize allogeneic platelet transfusions, and thereby reduce risk of transfusion-transmitted infection. Although there are other compelling medical, technical, and medical-legal reasons to use SDPs instead of RDPs, the authors believe that a decrease in allogeneic donor exposures alone is sufficient reason to make SDPs the platelet component of choice at their institutions.
通过输血治疗降低伤害患者风险的策略之一是限制输血传播疾病的总体风险。这种方法的核心是尽量减少患者接受的异体血液制品数量。成年患者通常的血小板剂量是6至10个随机供体血小板，而单采血小板（所谓的单供体单采血小板）为1个单位。因此，南加州大学健康科学园区（南加州大学大学医院、诺里斯癌症医院和洛杉矶县+南加州大学医学中心）的输血服务部门常规使用单供体单采血小板（SDP）而非随机供体血小板（RDP），以尽量减少异体血小板输血，从而降低输血传播感染风险。尽管使用SDP而非RDP还有其他令人信服的医学、技术和医疗法律原因，但作者认为，仅减少异体供体暴露这一点就足以使SDP成为其机构首选的血小板成分。
